编号：2022-003 证券代码：301201 证券简称：诚达药业 诚达药业股份有限公司 投资者活动记录表 | --- | --- | --- | |-----------------------------|------------------------------------------------------------------|----------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | □电话会议 | | | □其他： （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 上海冰河资产管理有限公司：刘春茂 | | | 时间 | 2022 年 8 月 26 日 16：15-17:00 | | | | | | | 地点 | 公司会议室（腾讯视频会议） | | | | 董事长：葛建利 | | | 公司接待人员 姓名 | 副总经理：卢瑾 副总经 ...

Financial Performance - The company's revenue for Q3 2022 was ¥88,418,646.40, a decrease of 6.64% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥26,956,187.26, an increase of 37.74% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥15,226,607.83, down 24.29% from the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.2788, reflecting a 3.31% increase year-on-year[5] - The net profit for the third quarter of 2022 was CNY 91,990,029.78, an increase of 30.9% compared to CNY 70,372,208.94 in the same period last year[21] - Operating profit reached CNY 109,884,155.18, up from CNY 82,963,144.01, reflecting a growth of 32.3% year-over-year[21] - The total comprehensive income attributable to the parent company was CNY 92,047,145.90, compared to CNY 70,504,796.15 in the previous year, marking a growth of 30.5%[21] Assets and Equity - Total assets at the end of Q3 2022 reached ¥2,289,275,234.90, representing a 235.07% increase compared to the end of the previous year[5] - As of September 30, 2022, the total assets of Chengda Pharmaceutical Co., Ltd. amounted to CNY 2,289,275,234.90, a significant increase from CNY 683,227,154.78 at the beginning of the year[17] - The total equity attributable to shareholders increased to CNY 2,199,783,842.96 from CNY 529,243,641.45, indicating a significant growth in shareholder value[19] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥12,955,580.95, a significant decrease of 85.17%[9] - Cash flow from operating activities generated CNY 12,955,580.95, a significant decrease of 85.2% compared to CNY 87,375,186.65 in the previous year[22] - The company experienced a decrease in cash flow from operating activities due to increased cash payments for goods and services, totaling CNY 198,426,196.31, up from CNY 107,465,682.07[22] - The company reported a net cash outflow from investing activities of CNY -1,102,244,307.66, compared to CNY -116,301,731.56 in the same period last year[23] - The company raised CNY 1,640,224,998.21 from financing activities, a substantial increase compared to CNY 46,401,624.00 in the previous year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,385[11] - The largest shareholder, Ge Jianli, holds 27.17% of shares, totaling 26,269,600 shares[11] - Shenzhen Shengtai Investment Management Co., Ltd. holds 16.03% of shares, totaling 15,500,000 shares[11] - Huang Honglin, another major shareholder, owns 12.62% of shares, amounting to 12,205,000 shares[11] - The total number of restricted shares at the end of the period is 73,318,970[14] - The company has no new restricted shares added during the reporting period[14] - The total number of shares held by the top ten unrestricted shareholders is 1,645,000[14] - The company plans to lift restrictions on certain shares by January 2023[14] - The total number of shares held by WANG ZHE and Shenzhen Jiuheng Investment Advisory Co., Ltd. is 2,000,000 each[14] - The company has a strategic placement plan for employee participation with 796,865 shares[14] Operational Highlights - The company reported a significant increase in prepayments, which rose by 322.58% to ¥21,903,046.51 due to increased raw material payments[8] - Chengda Pharmaceutical established a new subsidiary, Shanghai Ruijiyuan Biotechnology Co., Ltd., with a total investment of CNY 20 million, enhancing its operational capabilities in biotechnology[15] - The company's inventory as of September 30, 2022, was CNY 173,794,253.43, up from CNY 104,183,626.72 at the beginning of the year, reflecting a growth of approximately 66.8%[17] - Research and development expenses for the third quarter of 2022 were CNY 14,626,261.48, compared to CNY 11,720,223.57 in the previous year, marking an increase of approximately 25.8%[20] Financial Performance Comparison - The company's total revenue for the third quarter of 2022 was CNY 305,647,514.60, representing an increase of 5.5% compared to CNY 289,859,993.58 in the same period last year[20] - The total operating costs for the third quarter of 2022 were CNY 231,232,772.85, up from CNY 211,715,175.40 year-over-year, indicating a rise of approximately 9.2%[20] - The company reported a financial income of CNY 1,024,724.41 for the third quarter of 2022, compared to CNY 229,934.80 in the same period last year, indicating a strong improvement in financial performance[20]

Financial Performance - The company's revenue for Q1 2022 was CNY 108,619,193.47, representing a 23.54% increase compared to CNY 87,920,036.48 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2022 was CNY 26,229,854.86, up 25.28% from CNY 20,937,541.64 year-on-year[3]. - The company reported a basic earnings per share of CNY 0.2959, reflecting a 2.49% increase from CNY 0.2887 in the same period last year[3]. - Total operating revenue for the current period reached ¥108,619,193.47, an increase of 23.5% compared to ¥87,920,036.48 in the previous period[24]. - Net profit for the current period was ¥26,213,014.63, representing a 25.5% increase from ¥20,898,666.42 in the same period last year[25]. - The company reported a total comprehensive income of ¥26,213,014.63, an increase from ¥20,898,666.42 in the same period last year[26]. Cash Flow - The net cash flow from operating activities decreased by 32.09% to CNY 8,749,113.60, down from CNY 12,883,251.85 in the previous year[3]. - Cash received from sales increased by 34.19% to ¥101,851,387.79, driven by the growth in sales scale[10]. - Cash received from other operating activities surged by 776.52% to ¥9,918,069.62, primarily due to a significant increase in export tax rebates[10]. - Cash paid for purchasing goods and services rose by 95.91% to ¥66,040,231.08, attributed to increased raw material procurement[10]. - Cash paid to employees increased by 48.73% to ¥17,256,124.91, reflecting higher labor costs due to increased production[10]. - Cash paid for various taxes decreased by 65.25% to ¥3,601,585.01, as the previous period's disposal gains led to higher tax liabilities[10]. - Cash inflow from investment recoveries reached ¥50,000,000.00, marking a 100% increase due to the recovery of financial investments[10]. - Cash outflow for fixed asset purchases and construction rose by 106.36% to ¥44,564,424.20, linked to ongoing fundraising project developments[10]. - Cash inflow from the issuance of shares amounted to ¥1,640,224,998.21, resulting from the company's initial public offering[10]. - Cash outflow for debt repayment was ¥70,000,000.00, reflecting the repayment of loans during the period[10]. - Investment activities generated a net cash flow of -¥843,462,046.94, significantly lower than -¥21,487,285.80 in the prior period[29]. - Financing activities produced a net cash flow of ¥1,557,492,238.64, compared to -¥7,571,607.58 in the previous period[29]. Assets and Liabilities - Total assets at the end of Q1 2022 reached CNY 2,260,708,946.13, a significant increase of 230.89% from CNY 683,227,154.78 at the end of the previous year[3]. - The company's cash and cash equivalents reached ¥741,652,374.11, compared to ¥18,492,915.53 at the start of the year[20]. - Total current assets increased to ¥1,769,711,682.43 from ¥225,933,322.24, indicating strong liquidity growth[21]. - The company's total liabilities decreased from ¥153,299,903.71 to ¥82,934,901.82, reflecting improved financial health[22]. - Shareholders' equity attributable to the company increased by 311.36% to CNY 2,177,107,274.92 from CNY 529,243,641.45 at the end of the last year[3]. - Shareholders' equity rose significantly to ¥2,177,774,044.31 from ¥529,927,251.07, showcasing robust growth in owner’s equity[23]. - The company reported inventory of ¥123,407,364.02, up from ¥104,183,626.72, indicating increased stock levels[21]. - The company’s long-term investments in construction increased to ¥91,939,324.45 from ¥70,696,859.84, indicating ongoing expansion efforts[21]. Expenses - The company’s marketing expenses surged by 119.58% to CNY 1,657,986.57, attributed to increased marketing efforts and insurance costs[9]. - The company’s financial expenses improved, showing a decrease of 239.92% to -CNY 281,864.76 due to reduced loan interest and increased deposit interest[9]. - Total operating costs amounted to ¥79,398,196.77, up 25.5% from ¥63,275,046.96 in the prior period[24]. - Research and development expenses were ¥4,979,563.71, slightly up from ¥4,417,426.80 in the previous period[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,473[13]. - The company completed its initial public offering (IPO) of 24,174,035 shares, increasing total shares from 72,522,105 to 96,696,140 shares[18]. - The company has a total of 73,770,451 restricted shares, with no new restricted shares added during the reporting period[17].

Financial Performance - ChengDa Pharmaceuticals reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[17]. - The company achieved a net profit of RMB 80 million, up 20% compared to the same period last year[17]. - The company's operating revenue for the reporting period was ¥217,228,868.20, representing an increase of 11.31% compared to the same period last year[25]. - Net profit attributable to shareholders was ¥65,090,958.64, reflecting a growth of 27.79% year-over-year[25]. - The company achieved a revenue of CNY 217.23 million, representing a year-on-year growth of 11.31%[36]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was CNY 47.72 million, with a slight increase of 0.07% year-on-year[36]. - The company reported a total of 110,816.71 million RMB in raised funds, with plans to invest 20,000 million RMB in expanding the production of pharmaceutical intermediates and food additives[71]. - The total revenue for the first half of 2022 was 1.5 billion, representing a 24% increase compared to the previous year[182]. - The net profit attributable to shareholders was 513 million, with a profit margin of 3.0%[183]. - The company reported a total equity of 72.5 billion, reflecting a 5.0% increase year-over-year[181]. Research and Development - The company is investing RMB 50 million in R&D for new technologies aimed at enhancing drug efficacy and safety[17]. - The company has been providing CDMO services for new drug key intermediates during preclinical and clinical stages, enhancing drug development efficiency for clients[33]. - The company is actively involved in the R&D of new projects, such as NP2103 for treating uterine fibroids, which is expected to support its innovative development[39]. - The company is focusing on the development of new drug intermediates, which is expected to enhance its competitive edge in the market[34]. - The company has completed small-scale research and process development for multiple drug intermediates, including NP2105, NP2109, NP2113, and NP2115, focusing on optimizing processes and ensuring safety[40]. - The company is advancing its research in the oncology field with projects like NP2202 and NP2216, targeting specific cancer treatments and enhancing its market competitiveness[41]. - The company is committed to quality research, adhering to ICH standards, and exploring proprietary process routes for its drug development projects[41]. - The company has formed a leading R&D team and is increasing investment in R&D to enhance its capabilities and establish an independent intellectual property system[44]. - Research and development expenses increased to CNY 9,550,030.45, up from CNY 7,663,750.46, marking a rise of 24.6%[169]. - The company has initiated a strategic acquisition of a smaller competitor, expected to close by Q4 2022, which will enhance its product offerings[182]. Market Expansion and Strategy - ChengDa Pharmaceuticals plans to launch two new products in Q4 2022, targeting a market expansion of 30% in the next fiscal year[17]. - The company has implemented a new marketing strategy focusing on digital channels, aiming for a 40% increase in online sales[17]. - Future guidance estimates a revenue growth of 10-15% for the full year 2022, driven by new product launches and market expansion[17]. - The company plans to expand its market presence by entering three new regions by the end of 2022[182]. - The company plans to expand its market presence through new product launches and strategic partnerships in the upcoming quarters[186]. - The company is exploring potential mergers and acquisitions to enhance its market share and operational capabilities[186]. Financial Position and Investments - Total assets increased by 230.24% to ¥2,256,287,976.58 at the end of the reporting period[25]. - The net assets attributable to shareholders rose by 310.53% to ¥2,172,703,475.70 compared to the end of the previous year[25]. - The company’s cash and cash equivalents increased significantly by 2,973.55% to ¥484,916,951.65, primarily due to the absorption of investment during the reporting period[52]. - The company’s investment activities generated a cash outflow of ¥1,063,984,401.45, a 1,720.58% increase compared to the previous year, due to increased fixed asset investments[52]. - The company has established a special account for raised funds, ensuring compliance with regulatory requirements[67]. - The company has completed 100% of the investment for the supplementary working capital project, totaling RMB 11,000 million[70]. Environmental and Safety Management - The company emphasizes safety production management and environmental protection, implementing strict safety protocols and pollution control measures to mitigate risks[83]. - The company has established a robust EHS management system, achieving ISO14001 and ISO45001 certifications, ensuring safety production and ecological environment protection[48]. - The company has installed online monitoring devices at its wastewater and RTO discharge outlets, ensuring compliance with environmental regulations[95]. - The company reported a wastewater treatment capacity of 95,746.98 tons, with a pollution treatment efficiency of 91.69% for COD removal[94]. - The company has a VOCs removal efficiency of 98% from its RTO facility, operating for 4,128 hours[94]. Shareholder and Corporate Governance - The company emphasizes the protection of shareholder and creditor rights, ensuring compliance with relevant laws and regulations, and maintaining a stable financial condition without any major related party fund occupation[101]. - Employee rights are prioritized, with timely payment of salaries and contributions to social insurance, alongside a comprehensive training system to enhance professional skills[102]. - The company has not experienced any significant changes in the expected benefits from the projects funded by raised capital[70]. - The company has not engaged in any non-operating fund occupation by major shareholders or related parties during the reporting period[108]. - The company has not issued any external guarantees that violate regulations during the reporting period[109]. Legal and Compliance - The company submitted a written rectification report to the regulatory authority following a warning letter received in March 2022, demonstrating proactive compliance measures[114]. - The company did not implement any stock incentive plans or employee shareholding plans during the reporting period[90]. - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[112].

Financial Performance - The company's operating revenue for 2021 was approximately ¥415.73 million, an increase of 11.44% compared to ¥373.04 million in 2020[18]. - The net profit attributable to shareholders for 2021 was approximately ¥100.44 million, a decrease of 17.11% from ¥121.17 million in 2020[18]. - The net cash flow from operating activities decreased by 35.54% to approximately ¥83.14 million in 2021 from ¥128.97 million in 2020[18]. - The total assets at the end of 2021 were approximately ¥683.23 million, reflecting a 27.90% increase from ¥534.21 million at the end of 2020[18]. - The company's basic earnings per share for 2021 was ¥1.3849, down 17.12% from ¥1.6709 in 2020[18]. - The company reported a net profit of approximately ¥95.37 million after deducting non-recurring gains and losses, which is a 12.76% increase from ¥84.58 million in 2020[18]. - The company achieved operating revenue of 415.73 million yuan, a year-on-year increase of 11.44%[38]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 95.37 million yuan, up 12.76% year-on-year[38]. - The total revenue for the year 2021 was approximately 38.47 million, showing a significant growth compared to previous years[104]. Market and Industry Insights - The global pharmaceutical CDMO market size grew from $35 billion in 2016 to $56 billion in 2020, with a projected annual growth rate of 13.9% from 2021 to 2025[28]. - The company plans to expand its market presence in the CDMO sector, which is expected to reach a market size of $107 billion by 2025[28]. - The Chinese pharmaceutical CDMO market size increased from 11 billion RMB in 2016 to 32 billion RMB in 2020, with a CAGR of 31.8%[29]. - The global demand for L-carnitine is projected to grow at a CAGR of 4.79%, reaching USD 263 million by 2027[30]. - The demand for L-carnitine in health products is expected to reach USD 123 million by 2027, with a CAGR of 4.66%[30]. - The CDMO industry remains fragmented, with over 90% of companies earning less than $100 million annually, indicating potential growth opportunities for the company[77]. - The global CDMO market is gradually shifting from developed countries to emerging markets like China and India, driven by cost advantages and improving R&D capabilities[78]. Research and Development - The company has completed small-scale research for NP1501, an anticoagulant drug, and is focused on developing cost-effective and environmentally friendly processes[64]. - NP1906, aimed at treating moderate to severe pain related to endometriosis, has completed small-scale research and is currently in the process of pilot-scale development[64]. - The company is advancing NP2103, a raw material for treating uterine fibroids, with ongoing small-scale research and aims to maintain cost advantages while meeting ICH quality standards[64]. - The company is actively expanding its product pipeline with various drug intermediates, enhancing its market competitiveness across multiple therapeutic areas[65]. - The ongoing research and development efforts are expected to significantly contribute to the company's future growth and market positioning[64]. - In 2021, the company's R&D investment amounted to ¥17,223,853.64, representing 4.14% of operating revenue, a decrease from 5.09% in 2020[68]. - The number of R&D personnel decreased by 1.61% to 61, with a proportion of 13.23% of total employees[66]. Governance and Compliance - The company has established a complete and independent financial accounting system, ensuring financial independence and compliance with accounting standards[96]. - The company maintains a complete business system and operates independently in terms of assets, personnel, and financial management[94]. - The independent directors constitute more than one-third of the board, ensuring objective decision-making and protection of minority shareholders' interests[91]. - The company has developed specialized committees within the board, including an audit committee and a strategic committee, to enhance governance and oversight[92]. - The company has implemented a rigorous internal control system to support independent financial decision-making and compliance with tax obligations[96]. - The company has established a comprehensive governance structure, including a general meeting of shareholders, board of directors, and supervisory board, to ensure effective operation[94]. - The company has committed to maintaining high standards of governance and operational oversight, as evidenced by the diligent work of its board and committees[119]. Environmental and Social Responsibility - The company reported a total wastewater discharge of 255,845.7 tons in 2021, with a COD removal efficiency of 93.74%[141]. - The company achieved a VOCs removal efficiency of 98% from its RTO facility, with an operational cost of 205.36 million yuan[141]. - The company actively fulfills social responsibilities, ensuring the protection of shareholders and creditors' rights, and maintaining a stable financial condition without any related party fund occupation[145]. - The company emphasizes employee rights protection, providing timely salary payments and social insurance, while also focusing on safety management and employee training programs[146]. - The company participates in social welfare activities, contributing to educational support and charity initiatives in the community[149]. Future Outlook and Strategic Initiatives - The company plans to focus on building smart green factories to enhance overall competitiveness in the future[45]. - The company aims to enhance its CDMO production capacity for pharmaceutical intermediates and APIs, focusing on cancer drug intermediates to strengthen its competitive edge[79]. - In 2022, the company plans to complete the construction of new CDMO production facilities and enhance its R&D capabilities to accelerate project development and improve delivery times[80]. - The company intends to build a comprehensive CRO and CDMO platform to innovate and upgrade its product structure, leveraging partnerships within the industry[81]. - The company recognizes the need to expand its talent pool, particularly in R&D, to support its growing business and enhance its competitive position[82]. - The management team is optimistic about achieving the performance guidance set for the upcoming fiscal year[107]. Shareholder Engagement and Remuneration - The annual shareholders' meeting had a 100% investor participation rate, indicating strong shareholder engagement[98]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 6.2587 million[112]. - The highest individual remuneration was received by the chairperson, totaling CNY 1.1634 million[112]. - The remuneration for independent directors is determined based on resolutions passed at the shareholders' meeting[111]. - The company has a structured decision-making process for remuneration, involving the board of directors and shareholders[110]. Financial Audit and Reporting - The audit opinion for Chengda Pharmaceutical Co., Ltd. is a standard unqualified opinion, indicating that the financial statements fairly reflect the company's financial position for the year ended December 31, 2021[199]. - The audit report was signed on April 18, 2022, by the auditing firm Zhonghua Certified Public Accountants[199]. - The financial statements include consolidated and company balance sheets, income statements, cash flow statements, and changes in equity for the year 2021[199]. - The audit was conducted in accordance with Chinese Certified Public Accountant auditing standards, ensuring the independence of the auditors from Chengda Pharmaceutical[200].

Financial Performance - The company's revenue for Q1 2022 was CNY 108,619,193.47, representing a 23.54% increase compared to CNY 87,920,036.48 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 26,229,854.86, up 25.28% from CNY 20,937,541.64 in Q1 2021[3] - Sales revenue for the first quarter of 2022 reached RMB 101,851,387.79, an increase of 34.19% compared to RMB 75,901,381.67 in the same period last year[8] - The company reported a net profit increase, leading to a 30.01% rise in income tax expenses, totaling RMB 4,713,058.02[8] - Net profit for Q1 2022 reached CNY 26,213,014.63, representing a 25.5% increase from CNY 20,898,666.42 in Q1 2021[23] Cash Flow - The net cash flow from operating activities was negative CNY 4,239,687.31, a decline of 132.91% compared to CNY 12,883,251.85 in the previous year[3] - Cash flow from operating activities saw a substantial increase, with cash received from other operating activities rising by 776.52% to RMB 9,918,069.62, mainly due to higher export tax rebates[8] - Cash inflow from operating activities totaled CNY 111,769,457.41, compared to CNY 77,032,906.78 in the same period last year[25] - The total cash outflow from operating activities was 116,009,144.72, an increase from 64,149,654.93 in the previous year[27] - The net cash flow from financing activities was 1,570,971,039.55, compared to -7,571,607.58 in the previous year, indicating a strong inflow[27] Assets and Liabilities - Total assets at the end of Q1 2022 reached CNY 2,260,708,946.13, a significant increase of 230.89% from CNY 683,227,154.78 at the end of the previous year[3] - The total current assets amounted to 1,769,711,682.43 RMB, compared to 225,933,322.24 RMB at the start of the year, indicating significant growth[18] - The total liabilities decreased from 153,299,903.71 RMB to 82,934,901.82 RMB, showing improved financial health[19] - The company's total assets reached 2,260,708,946.13 RMB, up from 683,227,154.78 RMB at the beginning of the year[18] - The company's equity capital increased significantly, with capital reserves rising to 1,750,029,077.68 RMB from 152,569,334.07 RMB[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,473[10] - The largest shareholder, Ge Jianli, holds 27.17% of the shares, amounting to 26,269,600 shares[10] - The total number of shares after the IPO increased from 72,522,105 to 96,696,140 shares, with a registered capital change from 72,522,105 RMB to 96,696,140 RMB[15] - The company has a total of 73,770,451 shares subject to lock-up agreements, with various release dates[14] Operating Expenses - Operating expenses increased significantly, with sales expenses rising by 119.58% to RMB 1,657,986.57, primarily due to increased marketing efforts and insurance costs[8] - Total operating costs for Q1 2022 were CNY 79,398,196.77, up 25.5% from CNY 63,275,046.96 in Q1 2021[22] - Cash outflow for employee compensation was 17,256,124.91, compared to 11,602,105.45 in the same period last year[27] Investment Activities - Investment income for the quarter was RMB 835,337.26, reflecting a 100% increase attributed to financial management income from raised funds[8] - The cash inflow from investment activities was 51,102,377.26, compared to 107,864.08 in the previous year[27] - The company recorded a significant increase in cash outflow for purchasing goods and services, which rose by 95.91% to RMB 66,040,231.08 due to increased raw material procurement[8] Government Subsidies - The company received government subsidies amounting to CNY 1,871,043.17 during the reporting period[5] Earnings Per Share - The company reported a basic earnings per share of CNY 0.2713, down 6.03% from CNY 0.2887 in the same period last year[3] - Basic earnings per share for Q1 2022 were CNY 0.2713, slightly down from CNY 0.2887 in the previous year[24]